Bionet (1784) — Cash Flow Reinvestment Rate

Latest as of December 2025: 3.28x

Bionet (1784) has a Cash Flow Reinvestment Rate of 3.28x as of December 2025, reinvesting NT$93.46 Million (capex NT$38.02 Million plus investments NT$55.44 Million) from operating cash flow of NT$28.46 Million. Check 1784 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

3.28x
(Capex + Investments) / Operating CF

Total Reinvested

NT$93.46 Million
Capex + Investments

Operating Cash Flow

NT$28.46 Million
TWD

Capital Expenditures

NT$38.02 Million
TWD

Bionet Cash Flow Reinvestment Rate (2019–2025)

Historical reinvestment intensity for Bionet across 7 annual periods. Explore 1784 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Bionet (2019–2025)

Year-by-year capital reinvestment analysis for Bionet. For live market cap and broader valuation context, see Bionet market cap and net worth.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2025 2.04x NT$302.51 Million NT$148.04 Million NT$132.18 Million ▼ -53.3%
2024 4.38x NT$772.28 Million NT$176.49 Million NT$103.49 Million ▲ +53.6%
2023 2.85x NT$436.21 Million NT$153.09 Million NT$26.28 Million ▲ +653.0%
2022 0.38x NT$35.82 Million NT$94.65 Million NT$32.91 Million ▼ -82.4%
2021 2.15x NT$29.80 Million NT$13.88 Million NT$16.66 Million ▲ +101.9%
2020 1.06x NT$78.35 Million NT$73.66 Million NT$38.03 Million ▼ -95.0%
2019 21.27x NT$56.78 Million NT$2.67 Million NT$11.60 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow